Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5000 participants.
Also called NCT01186146
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 5,000 participants
- Registry
-
NCT01186146
-
- Other papers using this trial's data
- Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01186146. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)
- Acronym
- DES-LATE
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Aspirin monotherapy
- Intervention (Drug)
- Aspirin,Clopidogrel
- Lead sponsor
- Seung-Jung Park
- Collaborator
- CardioVascular Research Foundation, Korea
Record details
- Record id
cardio:ct-nct01186146- Content hash
62b95edab79058cdab212c719063b4eef0ee7b840d063119a7600f95cd57b1e3